Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 

Slides:



Advertisements
Similar presentations
Volume 42, Issue 1, Pages 7-11 (July 2002)
Advertisements

Volume 50, Issue 3, Pages (September 2006)
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Medical Management for BPH: The Role of Combination Therapy
Pascal Rischmann  European Urology Supplements 
Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Management of Acute and Chronic Retention in Men
Volume 54, Issue 6, Pages (December 2008)
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Rowland Illing  European Urology Supplements 
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Back to the Future: Introduction and Conclusions
Volume 52, Issue 3, Pages (September 2007)
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Rowland Illing  European Urology Supplements 
Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Volume 60, Issue 4, Pages (October 2011)
Counselling the Prostate Cancer Patient
Functional Bladder Problems
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Richard C. Harkaway  European Urology Supplements 
Volume 50, Issue 3, Pages (September 2006)
Volume 46, Issue 5, Pages (November 2004)
Tim Schneider  European Urology Supplements 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Transurethral Resection of the Prostate
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
The Importance of Testosterone Control in Prostate Cancer
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Neal Shore  European Urology Supplements 
Volume 54, Issue 6, Pages (December 2008)
When to Treat the Prostate, the Bladder, or Both?
Volume 72, Issue 2, Pages (August 2017)
Sergio Bracarda  European Urology Supplements 
Volume 53, Issue 6, Pages (June 2008)
Pharmacotherapy in Stress and Mixed Incontinence
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
Christian Stief  European Urology Supplements 
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC.
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Improving Flexibility and Quality of Life for Your Patients: A Must?
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
Economic and Social Impact of OAB
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Epidemiology and Demographics of Prostatitis
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette 
Presentation transcript:

Evaluation of Quality of Life and Quality of Sleep in Clinical Practice  Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements  Volume 6, Issue 9, Pages 576-584 (April 2007) DOI: 10.1016/j.eursup.2007.01.006 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Schematic representation of the definition of quality of life [14]. European Urology Supplements 2007 6, 576-584DOI: (10.1016/j.eursup.2007.01.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 In a randomised controlled trial including patients with type 2 diabetes, treatment with exenatide and insulin glargine significantly improved the vitality score of the SF-36 compared with baseline [34]. SF-36=Short Form-36 health survey questionnaire. European Urology Supplements 2007 6, 576-584DOI: (10.1016/j.eursup.2007.01.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 The mean vitality score (SF-36 quality of life score) is lower for patients with severe LUTS (IPSS 20–35) than for patients with other chronic diseases. (Adapted from reference 45.) The lower the score, the poorer the health. SF-36=Short Form-36 health survey questionnaire; LUTS=lower urinary tract symptoms; IPSS 20–35=International Prostate Symptom Score questions 20–35. European Urology Supplements 2007 6, 576-584DOI: (10.1016/j.eursup.2007.01.006) Copyright © 2007 European Association of Urology Terms and Conditions